Develops small-molecule and antisense medicines for people with epilepsy and movement disorders.
10-K for FY2025, filed Feb 19, 2026We are a fully integrated, leading central nervous system, or CNS, precision neuroscience biopharmaceutical company translating insights…View ↗
Cerebrum™, our small molecule platform, utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of…View ↗
Solidus™ (ASO platform)View ↗
Praxis works with Tenacia under an exclusive license to develop and commercialize ulixacaltamide in China, Hong Kong, Macau and Taiwan.
10-K for FY2025, filed Feb 19, 2026Our most advanced program, ulixacaltamide, is a differentiated and highly selective small molecule inhibitor of T-type calcium channels in…View ↗
10-Q for Q3 FY2026, filed Nov 9, 2026
−$94.2MView ↗
8-K, filed Jul 7, 2026
On July 7, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced that the Company entered into a research collaboration and…View ↗
8-K, filed Jul 2, 2026
On June 29, 2026, the Audit Committee of the Board of Directors (the "Audit Committee") of Praxis Precision Medicines, Inc. (the "Company")…View ↗
Ulixacaltamide advances
Ulixacaltamide has moved from clinical testing for essential tremor to an NDA submission and commercial preparations.
10-K for FY2022, filed Feb 7, 2023 10-K for FY2025, filed Feb 19, 2026Our most advanced program, ulixacaltamide, is a differentiated and highly selective small molecule inhibitor of T-type calcium channels…View ↗
We submitted a New Drug Application, or NDA, for ulixacaltamide for the treatment of ET to the FDA, and have commenced commercial…View ↗
Epilepsy pipeline focus
The earlier report centered its small-molecule discussion on a candidate for rare epilepsies; the latest describes relutrigine for developmental epilepsies and vormatrigine for common epilepsies.
10-K for FY2022, filed Feb 7, 2023 10-K for FY2025, filed Feb 19, 2026PRAX-562 for rare, monogenic DEEsView ↗
Competes with SK-Pharma, Xenon Pharmaceuticals, Biohaven Pharmaceuticals, Lundbeck, and Stoke Therapeutics
10-K for FY2025, filed Feb 19, 2026Approved therapies for ET, such as propranolol, and off-label therapies, such as primidone. Sodium channel blocker or similar ion…View ↗
Loading...